Seminars in Oncology
Volume 30, Issue 3 , Pages 349-360 , June 2003

Follow-up strategies after curative resection of colorectal cancer

  • Jeffrey A. Meyerhardt

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, USA
    • Department of Medicine, Harvard Medical School, USA
    • *Address reprint requests to Jeffrey A. Meyerhardt, MD, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115 USA
    • 1J.A.M. is a trainee in the Program in Cancer Epidemiology, National Research Service Award T32 CA 090001-27.
    • ,
  • Robert J. Mayer

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, USA
    • Department of Medicine, Harvard Medical School, USA

References 

  1. Jemal A, Murray T, Samuels A, et al.  Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26
  2. Jessup JM, Menck HR, Fremgen A, et al.  Diagnosing colorectal carcinoma: Clinical and molecular approaches. CA Cancer J Clin. 1997;47:70–92
  3. Guillem JG, Paty PB, Cohen AM. Surgical treatment of colorectal cancer. CA Cancer J Clin. 1997;47:113–128
  4. Chapuis PH, Dent OF, Fisher R, et al.  A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg. 1985;72:698–702
  5. Hughes KS, Simon R, Songhorabodi S, et al.  Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of patterns of recurrence. Surgery. 1986;100:278–284
  6. Ballantyne GH, Quin J. Surgical treatment of liver metastases in patients with colorectal cancer. Cancer. 1993;71:4252–4266
  7. Fong Y, Cohen AM, Fortner JG, et al.  Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938–946
  8. McAfee MK, Allen MS, Trastek VF, et al.  Colorectal lung metastases: Results of surgical excision. Ann Thorac Surg. 1992;53:780–786
  9. Erlichman C, Fine S, Wong A, et al.  A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol. 1988;6:469–475
  10. Petrelli N, Douglass HO, Herrera L, et al.  The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial.Gastrointestinal Tumor Study Group. J Clin Oncol. 1989;7:1419–1426
  11. Poon MA, O’Connell MJ, Moertel CG, et al.  Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989;7:1407–1418
  12. Glimelius B, Hoffman K, Olafsdottir M, et al.  Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: A randomized comparison of two regimens. Eur J Cancer Clin Oncol. 1989;25:829–835
  13. Cunningham D, Glimelius B, V301 Study Group . A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5- fluorouracil therapy. Semin Oncol. 1999;26:6–12
  14. Nordic Gastrointestinal Tumor Adjuvant Therapy Group . Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial. J Clin Oncol. 1992;10:904–911
  15. Saltz LB, Douillard JY, Pirotta N, et al.  Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: A new survival standard. Oncologist. 2001;6:81–91
  16. Saltz LB, Cox JV, Blanke C, et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med. 2000;343:905–914
  17. Douillard JY, Cunningham D, Roth AD, et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet. 2000;355:1041–1047
  18. Goldberg RM, Fleming TR, Tangen CM, et al.  Surgery for recurrent colon cancer: Strategies for identifying resectable recurrence and success rates after resection.Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med. 1998;129:27–35
  19. Quentmeier A, Schlag P, Smok M, et al.  Re-operation for recurrent colorectal cancer: The importance of early diagnosis for resectability and survival. Eur J Surg Oncol. 1990;16:319–325
  20. Desch CE, Benson AB, Smith TJ, et al.  Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol. 1999;17:1312–1321
  21. Kjeldsen BJ, Kronborg O, Fenger C, et al.  The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. Int J Colorectal Dis. 1997;12:329–334
  22. Beart RW, O’Connell MJ. Postoperative follow-up of patients with carcinoma of the colon. Mayo Clin Proc. 1983;58:361–363
  23. Cochrane JP, Williams JT, Faber RG, et al.  Value of outpatient follow-up after curative surgery for carcinoma of the large bowel. Br Med J. 1980;280:593–595
  24. de Vos W. Follow-up after colon cancer. In Colon and Rectal Cancer. In:  ed Edelstein P editors. New York, NY: Wiley-Liss,; 2000;p. 225–240
  25. Northover J. Follow-up after colorectal cancer resection: Is it worthwhile?. In Challenges in Colorectal Cancer. In:  ed Scholefield J editors. Oxford, UK: Blackwell Science,; 2000;p. 63–79
  26. Pietra N, Sarli L, Costi R, et al.  Role of follow-up in management of local recurrences of colorectal cancer: A prospective, randomized study. Dis Colon Rectum. 1998;41:1127–1133
  27. Makela JT, Laitinen SO, Kairaluoma MI. Five-year follow-up after radical surgery for colorectal cancer: Results of a prospective randomized trial. Arch Surg. 1995;130:1062–1067
  28. Ohlsson B, Breland U, Ekberg H, et al.  Follow-up after curative surgery for colorectal carcinoma: Randomized comparison with no follow-up. Dis Colon Rectum. 1995;38:619–626
  29. Bruinvels DJ, Stiggelbout AM, Kievit J, et al.  Follow-up of patients with colorectal cancer: A meta-analysis. Ann Surg. 1994;219:174–182
  30. Graham RA, Wang S, Catalano PJ, et al.  Postsurgical surveillance of colon cancer: Preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg. 1998;228:59–63
  31. Kjeldsen BJ, Thorsen H, Whalley D, et al.  Influence of follow-up on health-related quality of life after radical surgery for colorectal cancer. Scand J Gastroenterol. 1999;34:509–515
  32. Sugarbaker PH, Gianola FJ, Dwyer A, et al.  A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery. 1987;102:79–87
  33. Wanebo HJ, Llaneras M, Martin T, et al.  Prospective monitoring trial for carcinoma of colon and rectum after surgical resection. Surg Gynecol Obstet. 1989;169:479–487
  34. Minton JP, Hoehn JL, Gerber DM, et al.  Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer. 1985;55:1284–1290
  35. Tate H. Plasma CEA in the post-surgical monitoring of colorectal carcinoma. Br J Cancer. 1982;46:323–330
  36. Boey J, Cheung HC, Lai CK, et al.  A prospective evaluation of serum carcinoembryonic antigen (CEA) levels in the management of colorectal carcinoma. World J Surg. 1984;8:279–286
  37. Moertel CG, Fleming TR, Macdonald JS, et al.  An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270:943–947
  38. McCall JL, Black RB, Rich CA, et al.  The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum. 1994;37:875–881
  39. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum. 1994;37:272–277
  40. Hine KR, Dykes PW. Serum CEA testing in the post-operative surveillance of colorectal carcinoma. Br J Cancer. 1984;49:689–693
  41. Martin EW, Cooperman M, Carey LC, et al.  Sixty second-look procedures indicated primarily by rise in serial carcinoembryonic antigen. J Surg Res. 1980;28:389–394
  42. Posner MR, Mayer RJ. The use of serologic tumor markers in gastrointestinal malignancies. Hematol Oncol Clin North Am. 1994;8:533–553
  43. Denstman F, Rosen L, Khubchandani IT, et al.  Comparing predictive decision rules in postoperative CEA monitoring. Cancer. 1986;58:2089–2095
  44. Rocklin MS, Slomski CA, Watne AL. Postoperative surveillance of patients with carcinoma of the colon and rectum. Am Surg. 1990;56:22–27
  45. Devesa JM, Morales V, Enriquez JM, et al.  Colorectal cancer: The bases for a comprehensive follow-up. Dis Colon Rectum. 1988;31:636–652
  46. Schoemaker D, Black R, Giles L, et al.  Yearly colonoscopy, liver CT, and chest radiography do not influence 5- year survival of colorectal cancer patients. Gastroenterology. 1998;114:7–14
  47. McCormack PM, Attiyeh FF. Resected pulmonary metastases from colorectal cancer. Dis Colon Rectum. 1979;22:553–556
  48. Tornqvist A, Ekelund G, Leandoer L. The value of intensive follow-up after curative resection for colorectal carcinoma. Br J Surg. 1982;69:725–728
  49. Safi F, Beyer HG. The value of follow-up after curative surgery of colorectal carcinoma. Cancer Detect Prev. 1993;17:417–424
  50. Minsky BD, Mies C, Recht A, et al.  Resectable adenocarcinoma of the rectosigmoid and rectum: I. Patterns of failure and survival. Cancer. 1988;61:1408–1416
  51. Barkin JS, Cohen ME, Flaxman M, et al.  Value of a routine follow-up endoscopy program for the detection of recurrent colorectal carcinoma. Am J Gastroenterol. 1988;83:1355–1360
  52. Patchett SE, Mulcahy HE, O’Donoghue DP. Colonoscopic surveillance after curative resection for colorectal cancer. Br J Surg. 1993;80:1330–1332
  53. Barillari P, Ramacciato G, Manetti G, et al.  Surveillance of colorectal cancer: effectiveness of early detection of intraluminal recurrences on prognosis and survival of patients treated for cure. Dis Colon Rectum. 1996;39:388–393
  54. Luchtefeld MA, Ross DS, Zander JD, et al.  Late development of metachronous colorectal cancer. Dis Colon Rectum. 1987;30:180–184
  55. Cali RL, Pitsch RM, Thorson AG, et al.  Cumulative incidence of metachronous colorectal cancer. Dis Colon Rectum. 1993;36:388–393
  56. Bekdash B, Harris S, Broughton CI, et al.  Outcome after multiple colorectal tumours. Br J Surg. 1997;84:1442–1444
  57. Green RJ, Metlay JP, Propert K, et al.  Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med. 2002;136:261–269
  58. Heald RJ, Lockhart-Mummery HE. The lesion of the second cancer of the large bowel. Br J Surg. 1972;59:16–19
  59. Weir JA. Colorectal cancer: metachronous and other associated neoplasms. Dis Colon Rectum. 1975;18:4–5
  60. Welch JP. Multiple colorectal tumors: An appraisal of natural history and therapeutic options. Am J Surg. 1981;142:274–280
  61. Botsford TW, Aliapoulios MR, Fogelson FS. Results of treatment of colorectal cancer at the Peter Bent Brigham Hospital from 1960 to 1965. Am J Surg. 1971;121:398–402
  62. Devitt JE, Roth-Moyo LA, Brown FN. The significance of multiple adenocarcinomas of the colon and rectum. Ann Surg. 1969;169:364–367
  63. Neugut AI, Lautenbach E, Abi-Rached B, et al.  Incidence of adenomas after curative resection for colorectal cancer. Am J Gastroenterol. 1996;91:2096–2098
  64. Juhl G, Larson GM, Mullins R, et al.  Six-year results of annual colonoscopy after resection of colorectal cancer. World J Surg. 1990;14:255–261
  65. Weber CA, Deveney KE, Pellegrini CA, et al.  Routine colonoscopy in the management of colorectal carcinoma. Am J Surg. 1986;152:87–92
  66. Chen F, Stuart M. Colonoscopic follow-up of colorectal carcinoma. Dis Colon Rectum. 1994;37:568–572
  67. Winawer SJ, Zauber AG, Ho MN, et al.  Prevention of colorectal cancer by colonoscopic polypectomy: The National Polyp Study Workgroup. N Engl J Med. 1993;329:1977–1981
  68. Carlsson G, Petrelli NJ, Nava H, et al.  The value of colonoscopic surveillance after curative resection for colorectal cancer or synchronous adenomatous polyps. Arch Surg. 1987;122:1261–1263
  69. Kjeldsen BJ, Kronborg O, Fenger C, et al.  A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg. 1997;84:666–669
  70. Deveney KE, Way LW. Follow-up of patients with colorectal cancer. Am J Surg. 1984;148:717–722
  71. Hustinx R, Paulus P, Daenen F, et al.  Clinical value of positron emission tomography in the detection and staging of recurrent colorectal cancer. Gastroenterol Clin Biol. 1999;23:323–329
  72. Schiepers C, Penninckx F, De Vadder N, et al.  Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging. Eur J Surg Oncol. 1995;21:517–522
  73. Ruhlmann J, Schomburg A, Bender H, et al.  Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum. 1997;40:1195–1204
  74. Delbeke D, Vitola JV, Sandler MP, et al.  Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997;38:1196–1201
  75. Valk PE, Abella-Columna E, Haseman MK, et al.  Whole-body PET imaging with [18F] fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999;134:503–513
  76. Lai DT, Fulham M, Stephen MS, et al.  The role of whole-body positron emission tomography with [18F] fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg. 1996;131:703–707
  77. Virgo KS, Vernava AM, Longo WE, et al.  Cost of patient follow-up after potentially curative colorectal cancer treatment. JAMA. 1995;273:1837–1841
  78. Audisio RA, Setti-Carraro P, Segala M, et al.  Follow-up in colorectal cancer patients: A cost-benefit analysis. Ann Surg Oncol. 1996;3:349–357
  79. GIVIO Investigators . Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: A multicenter randomized controlled trial. JAMA. 1994;271:1587–1592
  80. Kievit J, Bruinvels DJ. Detection of recurrence after surgery for colorectal cancer. Eur J Cancer. 1995;31A:1222–1225
  81. Johnson FE, Longo WE, Vernava AM, et al.  How tumor stage affects surgeons’ surveillance strategies after colon cancer surgery. Cancer. 1995;76:1325–1329
  82. Johnson FE, McKirgan LW, Coplin MA, et al.  Geographic variation in patient surveillance after colon cancer surgery. J Clin Oncol. 1996;14:183–187
  83. Johnson FE, Novell LA, Coplin MA, et al.  How practice patterns in colon cancer patient follow-up are affected by surgeon age. Surg Oncol. 1996;5:127–131
  84. Vernava AM, Longo WE, Virgo KS, et al.  Current follow-up strategies after resection of colon cancer: Results of a survey of members of the American Society of Colon and Rectal Surgeons. Dis Colon Rectum. 1994;37:573–583
  85. Virgo KS, Wade TP, Longo WE, et al.  Surveillance after curative colon cancer resection: Practice patterns of surgical subspecialists. Ann Surg Oncol. 1995;2:472–482
  86. Richert-Boe KE. Heterogeneity of cancer surveillance practices among medical oncologists in Washington and Oregon. Cancer. 1995;75:2605–2612
  87. Benson AB, Desch CE, Flynn PJ, et al.  2000 Update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol. 2000;18:3586–3588
  88. Network NCC: Colon Cancer: Surveillance. www.nccn.org2002;
  89. Oncology ESfM: ESMO Minimum Clinical Recommendations for Diagnosis, Adjuvant Therapy and Follow-Up of Colon Cancer. www.esmo.org/reference/CC_adj.htm2002;
  90. Richard CS, McLeod RS. Follow-up of patients after resection for colorectal cancer: A position paper of the Canadian Society of Surgical Oncology and the Canadian Society of Colon and Rectal Surgeons. Can J Surg. 1997;40:90–100
  91. American Gastroenterology Association . New National Colorectal Cancer Practice Guidelines Recommend Life-Saving Tests. www.gastro.org/phys-sci/fact-sheets/newguidelines.html1997;

PII: S0093-7754(03)00095-2

Seminars in Oncology
Volume 30, Issue 3 , Pages 349-360 , June 2003

Article Tools